These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36807750)

  • 1.
    Flores Legarreta A; Salvo G; Gonzales NR; Chisholm G; Hillman RT; Frumovitz M
    J Gynecol Oncol; 2023 Jul; 34(4):e50. PubMed ID: 36807750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
    Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
    Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
    Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
    BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
    Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma.
    Muto Y; Ryo E; Namikawa K; Takahashi A; Ogata D; Fujimura T; Yatabe Y; Aiba S; Yamazaki N; Mori T
    Pathol Int; 2021 May; 71(5):337-347. PubMed ID: 33751708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic variability in the exon 19 of the RB1 gene and its flanking intronic sequences in HPV16-associated precancerous lesions in the Greek population.
    Tsakogiannis D; Moschonas GD; Daskou M; Stylianidou Z; Kyriakopoulou Z; Kottaridi C; Dimitriou TG; Gartzonika C; Markoulatos P
    J Med Microbiol; 2018 Nov; 67(11):1638-1644. PubMed ID: 30303478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging and staging of neuroendocrine cervical cancer.
    Elsherif S; Odisio EGLC; Faria S; Javadi S; Yedururi S; Frumovitz M; Ramalingam P; Bhosale P
    Abdom Radiol (NY); 2018 Dec; 43(12):3468-3478. PubMed ID: 29974177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
    Takayanagi D; Hirose S; Kuno I; Asami Y; Murakami N; Matsuda M; Shimada Y; Sunami K; Komatsu M; Hamamoto R; Kato MK; Matsumoto K; Kohno T; Kato T; Shiraishi K; Yoshida H
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
    Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
    Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
    Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
    BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.
    Hara Y; Shiba N; Yoshida K; Yamato G; Kaburagi T; Shiraishi Y; Ohki K; Shiozawa Y; Kawamura M; Kawasaki H; Sotomatsu M; Takizawa T; Matsuo H; Shimada A; Kiyokawa N; Tomizawa D; Taga T; Ito E; Horibe K; Miyano S; Adachi S; Taki T; Ogawa S; Hayashi Y
    Genes Chromosomes Cancer; 2023 Jul; 62(7):412-422. PubMed ID: 37102302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter study of the importance of systemic chemotherapy for patients with small-cell neuroendocrine carcinoma of the uterine cervix.
    Lee SW; Lim KT; Bae DS; Park SY; Kim YT; Kim KR; Nam JH
    Gynecol Obstet Invest; 2015; 79(3):172-8. PubMed ID: 25500455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations in retinoblastoma beyond RB1.
    Mendonça V; Evangelista AC; P Matta B; M Moreira MÂ; Faria P; Lucena E; Seuánez HN
    Exp Eye Res; 2021 Oct; 211():108753. PubMed ID: 34478740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
    Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
    Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.
    Afshar AR; Pekmezci M; Bloomer MM; Cadenas NJ; Stevers M; Banerjee A; Roy R; Olshen AB; Van Ziffle J; Onodera C; Devine WP; Grenert JP; Bastian BC; Solomon DA; Damato BE
    Ophthalmology; 2020 Jun; 127(6):804-813. PubMed ID: 32139107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence and survival in neuroendocrine cervical cancer.
    Stecklein SR; Jhingran A; Burzawa J; Ramalingam P; Klopp AH; Eifel PJ; Frumovitz M
    Gynecol Oncol; 2016 Dec; 143(3):552-557. PubMed ID: 27645621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.